FDA panel backs Puma Biotech's breast cancer drug

(Reuters) - Puma Biotechnology's experimental breast cancer drug reduces the risk of the disease returning and should be approved, an advisory committee to the U.S. Food and Drug Administration concluded on Wednesday, paving the way for its approval in patients who have already had their tumors surgically removed.